Revolution Medicines, Inc. (RVMDW) stock
RVMDWNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31Also trades as RVMD
$9.81+0.18 (+1.82%)
Close on Oct 30, 2026Market cap $41.00BP/E –Yield –
Revolution Medicines profit margin
Profit margin (net margin) is net income as a percentage of revenue.
Revolution Medicines's profit margin for the twelve months ending Sep 30, 2024 was -76423.3%. For fiscal 2023 it was -3768.3%, against -703.0% the year before. The highest annual figure on record is -95.2% in fiscal 2019.
Annual profit margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | -3768.3% | −3065.3 |
| FY2022 | Dec 31, 2022 | -703.0% | −66.4 |
| FY2021 | Dec 31, 2021 | -636.6% | −384.9 |
| FY2020 | Dec 31, 2020 | -251.6% | −156.4 |
| FY2019 | Dec 31, 2019 | -95.2% | +112.0 |
| FY2018 | Dec 31, 2018 | -207.2% | – |
Quarterly profit margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q4 FY2023 | Dec 31, 2023 | -21770.5% | −19585.5 |
| Q2 FY2023 | Jun 30, 2023 | -2570.6% | −1899.0 |
| Q1 FY2023 | Mar 31, 2023 | -970.9% | −210.2 |
| Q4 FY2022 | Dec 31, 2022 | -368.6% | +188.2 |
| Q3 FY2022 | Sep 30, 2022 | -2185.0% | +2623.3 |
| Q2 FY2022 | Jun 30, 2022 | -671.6% | −162.3 |
| Q1 FY2022 | Mar 31, 2022 | -760.7% | −393.8 |
| Q4 FY2021 | Dec 31, 2021 | -556.8% | −166.0 |
| Q3 FY2021 | Sep 30, 2021 | -4808.4% | −4593.4 |
| Q2 FY2021 | Jun 30, 2021 | -509.3% | −237.8 |
| Q1 FY2021 | Mar 31, 2021 | -367.0% | −197.9 |
| Q4 FY2020 | Dec 31, 2020 | -390.9% | −270.1 |
| Q3 FY2020 | Sep 30, 2020 | -215.0% | −112.5 |
| Q2 FY2020 | Jun 30, 2020 | -271.5% | −189.1 |
| Q1 FY2020 | Mar 31, 2020 | -169.1% | −92.1 |
| Q4 FY2019 | Dec 31, 2019 | -120.7% | – |
| Q3 FY2019 | Sep 30, 2019 | -102.5% | – |
| Q2 FY2019 | Jun 30, 2019 | -82.4% | – |
| Q1 FY2019 | Mar 31, 2019 | -76.9% | – |